Anticoagulation Again Flops for Outpatient COVID-19
CHICAGO — For outpatient COVID-19, prophylactic anticoagulation with rivaroxaban (Xarelto) did not improve outcomes in elevated thrombotic risk patients, the PREVENT trial showed. Compared with placebo, giving the direct-acting oral anticoagulant (DOAC) for 35 days in non-hospitalized patients with symptomatic COVID-19 who had at least one risk factor for thrombosis didn’t reduce thromboembolic events or […]